A Phase 3 interventional study of TRC101 and Placebo in Metabolic Acidosis and Chronic Kidney Disease, sponsored by Tricida, Inc.. Terminated at 203 sites in 34 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-14.
Sponsored by Tricida, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Acidosis with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Acidosis · United States.
Among the 30 studies in Acidosis with a site in United States, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 18th registered.
111 studies on the registry are indexed under Acidosis; 19 are open to participants now.
Browse Acidosis studies →7 of the 30 studies in Acidosis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 21+
Renibus Therapeutics, Inc. · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of California, Davis · Sites in United States
Ages 21–85
University of Colorado, Denver · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Acidosis studies recruiting now, 13 (76%) set no upper age limit and 2 (12%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 8 · Phase 4 4
First in 2003; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,480 is above the median of 52 across 79 interventional studies indexed under Acidosis.
Median enrollment 40 across the 29 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 30 have an industry lead sponsor. The 10 most frequent:
Tricida, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Tricida, Inc. has 4 studies filed under Acidosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Acidosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355062Phase 3Renibus Therapeutics, Inc.A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis | 2027-06 |
| NCT04984226University of California, DavisSodium Bicarbonate and Mitochondrial Energetics in Persons With CKD | 2026-12-31 |
| NCT04159103ModernaTX, Inc.Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Acidosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of TRC101 on the progression of chronic kidney disease (CKD) and to evaluate the safety profile of TRC101 in CKD patients with metabolic acidosis.
This is a randomized, double-blind, placebo-controlled trial. Eligible subjects will be randomized in a 1:1 ratio to TRC101 or placebo. The primary endpoint of the study will be progression of renal disease, defined by time to first occurrence of any event in the composite endpoint consisting of a confirmed ≥ 40% reduction in eGFR, end-stage renal disease (ESRD), and renal death. The study will terminate when the independent blinded Clinical Endpoint Adjudication Committee has positively adjudicated the targeted number of primary efficacy endpoint events. The maximum duration of follow-up for a randomized subject is anticipated to be approximately 6 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TRC101
Drug: Placebo
Oral, non-absorbed, polymeric hydrochloric acid binder
Also known as: Veverimer
Placebo comparator
Progression of chronic kidney disease
Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death.
Time frame: Through study completion, up to approximately 6 years.
Death (all-cause), ESRD or a confirmed ≥50% reduction in eGFR
Time to first occurrence of: death (all-cause); ESRD; a confirmed ≥50% reduction in eGFR.
Time frame: Through study completion, up to approximately 6 years.
Physical functioning (subjective)
Kidney Disease Quality of Life Physical Functioning Survey.
Time frame: 18 months after randomization.
Physical functioning (objective)
Repeated chair stand test.
Time frame: 18 months after randomization.
ESRD or renal death
Time to ESRD or renal death.
Time frame: Through study completion, up to approximately 6 years.
Primary outcome measure OR cardiovascular death
Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death; cardiovascular death.
Time frame: Through study completion, up to approximately 6 years.
Serum creatinine
Time to first occurrence of a confirmed doubling of serum creatinine.
Time frame: Through study completion, up to approximately 6 years.
≥50% reduction in eGFR
Time to first occurrence of a confirmed ≥50% reduction in eGFR.
Time frame: Through study completion, up to approximately 6 years.
≥40% reduction in eGFR
Time to first occurrence of a confirmed ≥40% reduction in eGFR.
Time frame: Through study completion, up to approximately 6 years.
All-cause hospitalization
Frequency of all-cause hospitalization.
Time frame: Through study completion, up to approximately 6 years.
Cardiovascular death
Time to cardiovascular death.
Time frame: Through study completion, up to approximately 6 years.
All-cause mortality
Time to all-cause mortality.
Time frame: Through study completion, up to approximately 6 years.
Safety of TRC101
Frequency, intensity, and relationship to study drug of adverse events and serious adverse events.
Time frame: Through study completion, up to approximately 6 years.
Showing the first 100 of 203 sites across 34 countries. Choose a country and city above to see the rest.
Plan to share: No
Ran from Nov 2018 to primary completion in Aug 2022, 45 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Veverimer
Tricida, Inc.